The very slow roll of Bio­gen's Aduhelm: Neu­rol­o­gists weigh in on pa­tients, prac­tices and pay­ments amid on­go­ing me­dia storm

Five months af­ter the ap­proval of Bio­gen’s Aduhelm, the bad news just keeps pil­ing up for the Alzheimer’s drug. The con­fir­ma­tion yes­ter­day of a Bio­gen in­ves­ti­ga­tion in­to the death of tri­al par­tic­i­pant is the lat­est set­back, but it adds to a laun­dry list of on­go­ing woes in­clud­ing in­sur­ance re­im­burse­ment un­cer­tain­ty, dis­mal ini­tial sales, a la­bel flipflop, FDA ad­vi­so­ry com­mit­tee mem­bers re­sign­ing and out­spo­ken re­searchers and pub­lic of­fi­cials who con­tin­ue to ques­tion the drug’s ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.